Paraprobiotics are inactivated microbial cells or their components: bacteria that have been rendered incapable of replication but that retain structural molecules, such as cell wall fragments, surface proteins, and other immunologically active constituents. Because the cells are dead, they carry none of the risks associated with applying live microorganisms to an open wound—no chance of opportunistic infection, no uncontrolled proliferation in immunocompromised tissue, and fewer concerns about horizontal gene transfer. Yet the evidence base for probiotics suggests that many of their beneficial effects on the immune system do not require viability at all. The molecular patterns displayed by inactivated cells can still be recognized by innate immune receptors, modulating inflammatory signaling pathways in ways that may be therapeutically useful. The Iranian team set out to test whether this immunomodulatory potential could be harnessed in one of the most hostile settings in wound care: a burn wound colonized by aggressive bacteria.

The experimental design was deliberately structured to isolate the effects of the paraprobiotic treatment. The researchers created burn injuries in mice and introduced bacterial infections, then divided the animals into twelve groups of three mice each. Different groups received paraprobiotics, conventional antibiotics, or the respective control treatments, allowing direct comparison between the novel biological therapy and the established pharmaceutical approach. The model targeted second-degree burns, in which damage extends through the epidermis into part of the dermis—a depth that makes these wounds particularly vulnerable to infection and clinically significant in human patients. The work was approved by the ethics committee of the Pasteur Institute of Iran and conducted in accordance with the Declaration of Helsinki, and the study was supported by a grant from the Pasteur Institute of Iran.

What distinguishes this study from many previous evaluations of probiotic-derived therapies is the breadth of the measurements. Rather than simply tracking wound size over time, the researchers performed quantitative gene expression analysis on tissue from the wounds, profiling a panel of genes that captures both sides of the healing equation. On the inflammatory side, they measured the messenger RNA levels of three canonical proinflammatory cytokines: interleukin-1 (IL-1), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-α). These molecules orchestrate the early immune response to infection and injury, recruiting immune cells and amplifying antimicrobial defenses, but when their production persists unchecked they become destructive, degrading surrounding tissue and converting a contained injury into a chronic, inflamed wound bed.

On the repair side, the panel included interleukin-10 (IL-10), the body’s principal anti-inflammatory cytokine, which acts as a molecular brake on excessive immune activation; insulin-like growth factor 1 (IGF-1), which stimulates cell proliferation and supports the regeneration of skin structures; and transforming growth factor-beta (TGF-β) together with SMAD2, a signaling intermediate that transmits TGF-β signals into the nucleus. The TGF-β/SMAD axis is central to the later phases of wound healing, driving fibroblast activation, collagen deposition, and the orderly remodeling that turns a raw wound into restored, functional tissue. By quantifying all of these transcripts, the team could ask not just whether the wounds healed faster under paraprobiotic treatment, but whether the underlying immunological program had genuinely shifted from a destructive inflammatory state toward a constructive, regenerative one.

The results, as reported in the paper, were striking on both fronts. Paraprobiotic intervention had a major impact on wound healing and on the suppression of bacterial virulence factors—the molecular tools that pathogens use to adhere to tissue, evade immune defenses, and damage host cells. Suppressing virulence rather than bacterial growth represents a fundamentally different therapeutic logic from antibiotics. Instead of imposing a lethal selection pressure that drives resistance, anti-virulence strategies disarm the pathogen, allowing the host’s own defenses to clear the infection. In an era when resistant strains of Pseudomonas aeruginosa and Staphylococcus aureus—two of the most notorious burn wound pathogens, and both listed among the study’s keywords—routinely defeat last-line antibiotics, therapies that reduce the harm bacteria can do, rather than the bacteria themselves, are attracting intense interest.

The gene expression data reinforced the clinical picture. In the paraprobiotic-treated group, the proinflammatory cytokines IL-1, IL-6, and TNF-α were significantly downregulated compared with the control groups, indicating that the treatment had quieted the destructive inflammatory storm in the wound. At the same time, the anti-inflammatory and tissue repair genes—IL-10, IGF-1, SMAD2, and TGF-β—were upregulated, showing that the wound environment had shifted toward the molecular program of active reconstruction. This coordinated pattern matters because healing is not simply the absence of inflammation; it requires a precisely timed transition from the inflammatory phase to the proliferative and remodeling phases. A therapy that simultaneously reduces inflammatory signaling and elevates repair-associated signaling is effectively accelerating that transition, which is consistent with the observed improvement in wound outcomes.

The authors conclude that paraprobiotics possess strong immunomodulatory and regenerative properties that enhance wound repair, making them promising agents for safer and more effective management of infected burn wounds. The framing is important: the value proposition of paraprobiotics is not that they out-kill antibiotics, but that they address the two intertwined problems of infected burns—uncontrolled inflammation and bacterial aggression—with a single intervention that carries a favorable safety profile. Because the therapeutic agent is non-viable, it can be standardized, sterilized, and stored without the cold-chain and contamination concerns that complicate live biotherapeutics. The researchers argue that their results support the development of natural therapeutic approaches designed to maximize patient outcomes in burn care.

As with any early-stage animal study, the usual caveats apply. The experiment involved small groups of mice, and the translation from a murine model to human burn units—a setting where wound depth, patient comorbidities, and polymicrobial infections add layers of complexity—will require substantially more work. The published version is an early-release, peer-reviewed accepted manuscript that remains subject to further editorial edits. Nevertheless, the study adds to a growing body of evidence that the therapeutic potential of probiotic organisms does not end when their viability does. If subsequent studies confirm that inactivated probiotic cells can reliably suppress bacterial virulence and reprogram wound inflammation in humans, paraprobiotics could find a place alongside antibiotics in the treatment of infected burns—offering clinicians a tool that works with the immune system rather than merely against the microbe, at a time when the alternatives are narrowing.

Subject of Research: Paraprobiotic therapy for infected burn wounds in a mouse model

Article Title: Paraprobiotics suppress bacterial virulence and promote anti-inflammatory tissue repair in a murine infected burn wound model

Article References: Salimi, A., Torkamaneh, M., Haghighatshenas, Z., Sakaki, F., Chiani, M., Sohrabi, A., Aghamohammad, S., & Rohani, M. (2026). Paraprobiotics suppress bacterial virulence and promote anti-inflammatory tissue repair in a murine infected burn wound model. Scientific Reports. https://doi.org/10.1038/s41598-026-75233-5

Image Credits: AI Generated

DOI: 10.1038/s41598-026-75233-5

Keywords: paraprobiotics, burn wounds, wound healing, bacterial virulence, inflammatory cytokines, IL-10, TGF-beta, Pseudomonas aeruginosa, Staphylococcus aureus, mouse model, immunomodulation, antibiotic alternatives

The study, published in BMC Plastic and Reconstructive Surgery, included 50 consecutive patients whose wounds were classified as chronic, surgical, or deep second- and third-degree burns. The median age of participants was 50 years, and the population reflected the challenging clinical reality of tertiary outpatient wound care: 56 percent had a history of chronic medical illness such as diabetes mellitus or hypertension, and 48 percent were smokers, both well-known factors that impair tissue repair. Wound types were evenly split between surgical and chronic wounds at 22 percent each, with 12 percent being burn injuries. Wound sizes ranged from 4 to 110 square centimeters, with a median of 20 square centimeters, meaning that many of these lesions were substantial tissue defects rather than minor abrasions.

The treatment protocol itself reflected practical bedside medicine rather than laboratory conditions. The gel was typically initiated once the wound was clinically clean and open rather than immediately after injury, applied once to twice daily depending on severity and clinical judgment. A standardized alternating-day approach was generally followed, with gel application and dressing on the first day followed by open wound exposure on the second, repeated cyclically. Nineteen patients also received negative pressure wound therapy using Vacuum-Assisted Closure at an average setting of 120 mmHg before or during gel treatment, usually for complex or highly exudative wounds that first needed to be converted into a clean open wound bed. The duration of gel application ranged from 7 to 70 days, with a median of roughly three weeks.

The primary endpoint was deliberately designed as a composite: either complete wound healing, defined as 100 percent epithelialization with no drainage sustained for at least two weeks, or a ready-to-graft state characterized by healthy granulation tissue, absence of necrotic material, minimal exudate, and no clinical signs of infection. Median time to reaching this composite endpoint was 21 days. Every one of the six burn wounds in the cohort healed completely, as did 63.6 percent of chronic wounds and 50 percent of surgical wounds, although the differences across wound types did not reach statistical significance. The researchers are careful to note that the small burn subgroup should be interpreted with caution, and that no gel-related adverse events such as dermatitis, allergic reactions, or wound deterioration were documented anywhere in the records.

When the team applied multivariable Cox proportional hazards regression to identify independent predictors of healing, one variable stood out clearly: wound size. After adjusting for age, chronic disease, smoking status, and wound dimensions, larger wounds were associated with a significantly lower hazard of healing over time, with a hazard ratio of 0.97 (95 percent confidence interval 0.95 to 0.99, P = 0.002). Age, chronic comorbidity, and smoking showed no significant independent associations with time to healing in this cohort. The duration of gel use was also statistically associated with the outcome, but the authors explicitly warn against reading this as evidence that longer application is independently therapeutic; treatment duration is a time-dependent variable that naturally extends in slow-healing wounds, a phenomenon of reverse causation and potential immortal time bias that the team flags as hypothesis-generating only.

The mechanistic rationale behind the formulation rests on the complementary biology of its components. Hyaluronic acid, a glycosaminoglycan naturally present in the extracellular matrix, plays multifaceted roles across every phase of wound repair, from hemostasis through inflammation, proliferation, angiogenesis and remodeling. Its effects are molecular-weight dependent, and clinical evidence supports its value: a Cochrane systematic review of randomized controlled trials concluded that hyaluronic acid dressings significantly improve ulcer healing compared with neutral vehicle, with a risk ratio of 2.11. By keeping the wound moist, hyaluronic acid enhances cell migration, supports growth factor activity, and facilitates autolytic debridement, all of which accelerate the regenerative cascade.

Alginate, a natural polymer derived from brown seaweed, brings a different but equally important set of properties, particularly for wounds producing moderate to heavy exudate. Alginate dressings absorb excess fluid while forming a protective gel barrier that maintains moisture balance at the wound interface, preventing the desiccation-induced cellular damage that stalls healing. An updated systematic review and meta-analysis encompassing 42 randomized controlled trials and 2,536 individuals found that alginate dressings significantly reduced healing time by an average of 4.58 days, accelerated granulation tissue formation, and reduced the frequency of dressing changes compared with conventional dressings. The third pillar, antimicrobial enzymes, targets one of the most stubborn obstacles in chronic wound care: biofilm.

Chronic wounds frequently harbor complex polymicrobial biofilm communities, dominated by organisms such as Staphylococcus aureus and Pseudomonas aeruginosa, encased in protective extracellular polymeric matrices that confer up to a thousand-fold increase in antibiotic resistance compared with free-floating bacteria. These biofilms perpetuate inflammation and block progression through the normal healing phases. Proteolytic and antimicrobial enzymes offer a strategy to degrade biofilm structural proteins, improve antimicrobial penetration, and modulate the excessive proteolytic activity that characterizes chronic wound microenvironments. While the Egyptian study did not directly measure microbial burden or biofilm presence, the authors suggest that the strong outcomes observed in chronic wounds are consistent with the enzymes contributing to infection control and wound bed optimization, even though the exact proprietary concentrations of the ingredients were not available to the investigators.

The clinical case series embedded in the study illustrates the breadth of scenarios in which the gel was used. A post-assault crush wound on the ulnar aspect of the hand and forearm, with exposed paratenon, showed progressive granulation and marginal epithelialization under twice-daily dressings. Crushed wounds of the fingers healed completely without grafts or flaps, and a severe open ankle fracture with lacerated toe extensors was optimized for grafting through daily gel application. A dramatic degloving injury of the entire left leg, managed initially with surgical debridement and vacuum therapy, developed healthy granulation tissue after 50 days of combined treatment and became ready for split-thickness skin grafting. Perhaps most striking, a third-degree burn on the forearm achieved complete epithelialization after only five days of daily dressings, healing without any surgical intervention.

The authors and outside observers alike stress that these findings must be framed within the study’s design. As a retrospective, single-center, single-arm analysis without a control group, it cannot establish that the gel, rather than natural healing trajectories, debridement, vacuum therapy, antibiotics, or surgeon expertise, caused the observed outcomes. Records did not capture the total population of wound patients treated during the period, vascular assessment did not routinely include ankle-brachial index measurements, and the composite endpoint merges two clinically distinct outcomes. Still, the investigators argue that real-world evidence of this kind fills a genuine gap, especially in low- and middle-income settings where accessible, easily applied topical agents can meaningfully reduce the need for early surgery, shorten time to definitive closure, and lower treatment costs. The team calls for multicenter, double-blind, randomized controlled trials comparing the gel against standard wound care to determine whether these promising signals hold up under rigorous scrutiny.

Subject of Research: Clinical evaluation of a hyaluronic acid-based topical gel for wound bed preparation and healing in chronic, surgical, and burn wounds

Article Title: Real-world clinical evaluation of Zymalge® gel for optimizing wound bed prior to skin grafting or spontaneous healing: a retrospective single-arm cohort study

Article References: Amin, M. A., Salah, A. E., Farag, R. S., & Elosh, A. M. M. (2026). Real-world clinical evaluation of Zymalge® gel for optimizing wound bed prior to skin grafting or spontaneous healing: a retrospective single-arm cohort study. BMC Plastic and Reconstructive Surgery, 2(1), Article 18. https://doi.org/10.1186/s44452-026-00029-5

Image Credits: AI Generated

DOI: 10.1186/s44452-026-00029-5

Keywords: wound healing, Zymalge gel, hyaluronic acid, alginate dressings, chronic wounds, burn wounds, skin grafting, wound bed preparation, antimicrobial enzymes, biofilm, plastic surgery, retrospective cohort study